Trial
NCT01083966
Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Northwell Health
Collaborators
Feinstein Institute for Medical Research; Hofstra North Shore
Condition
Vestibular Schwannoma
Intervention
Bevacizumab (Avastin)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-01